Monitoring CD3(+) T Cells in Kidney Transplantation and Immunosuppression Adequacy
Transplantation Proceedings, cilt.57, sa.9, ss.1715-1720, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 57 Sayı: 9
- Basım Tarihi: 2025
- Doi Numarası: 10.1016/j.transproceed.2025.06.016
- Dergi Adı: Transplantation Proceedings
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE
- Sayfa Sayıları: ss.1715-1720
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Background: Monitoring CD3(+) T-cell counts in kidney transplant recipients can provide valuable insights into immunosuppressive therapy effectiveness. This study aimed to evaluate the use of CD3(+) T-cell levels as biomarkers for immunosuppression adequacy and to assess their predictive value for acute rejection post-transplantation. Methods: A retrospective review was conducted involving 130 kidney transplant recipients who received induction therapy with antithymocyte globulin (ATG). CD3(+) T-cell percentages and absolute counts were measured using flow cytometry on postoperative day 5. Immunosuppression was maintained with tacrolimus, initiated upon clinical indicators of graft function recovery. Results: Among monitored patients, the median CD3(+) T-cell percentage was 48%, and median absolute count was 0.14 × 10⁹/L. Acute rejection occurred in 9.9% of recipients. Higher CD3(+) T-cell values significantly correlated with acute rejection (64.0% vs 47.5%, p = .011; absolute count 0.28 vs 0.13 × 10⁹/L, p = .032). ROC analysis identified optimal predictive thresholds: 54% for CD3(+) percentage (sensitivity 85.7%, specificity 73.4%) and 0.21 × 10⁹/L for absolute count (sensitivity 85.7%, specificity 75.0%). Conclusions: CD3(+) T-cell monitoring effectively guides individualized immunosuppressive strategies, significantly predicting acute rejection risks and optimizing graft outcomes.